Neuren Pharmaceuticals' market value is the price at which a share of Neuren Pharmaceuticals trades on a public exchange. It measures the collective expectations of Neuren Pharmaceuticals Limited investors about its performance. Neuren Pharmaceuticals is trading at 12.89 as of the 25th of December 2025. This is a No Change since the beginning of the trading day. The stock's lowest day price was 12.89. With this module, you can estimate the performance of a buy and hold strategy of Neuren Pharmaceuticals Limited and determine expected loss or profit from investing in Neuren Pharmaceuticals over a given investment horizon. Check out Neuren Pharmaceuticals Correlation, Neuren Pharmaceuticals Volatility and Neuren Pharmaceuticals Alpha and Beta module to complement your research on Neuren Pharmaceuticals.
Please note, there is a significant difference between Neuren Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuren Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuren Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Neuren Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Neuren Pharmaceuticals' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Neuren Pharmaceuticals.
0.00
06/28/2025
No Change 0.00
0.0
In 5 months and 30 days
12/25/2025
0.00
If you would invest 0.00 in Neuren Pharmaceuticals on June 28, 2025 and sell it all today you would earn a total of 0.00 from holding Neuren Pharmaceuticals Limited or generate 0.0% return on investment in Neuren Pharmaceuticals over 180 days. Neuren Pharmaceuticals is related to or competes with Molecular Partners, MediciNova, Anebulo Pharmaceuticals, Champions Oncology, Enliven Therapeutics, MoonLake Immunotherapeuti, and Structure Therapeutics. Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders More
Neuren Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Neuren Pharmaceuticals' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Neuren Pharmaceuticals Limited upside and downside potential and time the market with a certain degree of confidence.
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neuren Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Neuren Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Neuren Pharmaceuticals historical prices to predict the future Neuren Pharmaceuticals' volatility.
Neuren Pharmaceuticals appears to be somewhat reliable, given 3 months investment horizon. Neuren Pharmaceuticals has Sharpe Ratio of 0.0476, which conveys that the firm had a 0.0476 % return per unit of risk over the last 3 months. We have found eighteen technical indicators for Neuren Pharmaceuticals, which you can use to evaluate the volatility of the firm. Please exercise Neuren Pharmaceuticals' Risk Adjusted Performance of 0.042, mean deviation of 1.88, and Standard Deviation of 4.66 to check out if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Neuren Pharmaceuticals holds a performance score of 3. The company secures a Beta (Market Risk) of 0.96, which conveys possible diversification benefits within a given portfolio. Neuren Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Neuren Pharmaceuticals is expected to follow. Please check Neuren Pharmaceuticals' market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness , to make a quick decision on whether Neuren Pharmaceuticals' current price movements will revert.
Auto-correlation
-0.39
Poor reverse predictability
Neuren Pharmaceuticals Limited has poor reverse predictability. Overlapping area represents the amount of predictability between Neuren Pharmaceuticals time series from 28th of June 2025 to 26th of September 2025 and 26th of September 2025 to 25th of December 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Neuren Pharmaceuticals price movement. The serial correlation of -0.39 indicates that just about 39.0% of current Neuren Pharmaceuticals price fluctuation can be explain by its past prices.
Correlation Coefficient
-0.39
Spearman Rank Test
-0.16
Residual Average
0.0
Price Variance
1.0
Neuren Pharmaceuticals lagged returns against current returns
Autocorrelation, which is Neuren Pharmaceuticals pink sheet's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Neuren Pharmaceuticals' pink sheet expected returns. We can calculate the autocorrelation of Neuren Pharmaceuticals returns to help us make a trade decision. For example, suppose you find that Neuren Pharmaceuticals has exhibited high autocorrelation historically, and you observe that the pink sheet is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values
Timeline
Neuren Pharmaceuticals regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Neuren Pharmaceuticals pink sheet is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Neuren Pharmaceuticals pink sheet is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Neuren Pharmaceuticals pink sheet over time.
Current vs Lagged Prices
Timeline
Neuren Pharmaceuticals Lagged Returns
When evaluating Neuren Pharmaceuticals' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Neuren Pharmaceuticals pink sheet have on its future price. Neuren Pharmaceuticals autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Neuren Pharmaceuticals autocorrelation shows the relationship between Neuren Pharmaceuticals pink sheet current value and its past values and can show if there is a momentum factor associated with investing in Neuren Pharmaceuticals Limited.
Other Information on Investing in Neuren Pink Sheet
Neuren Pharmaceuticals financial ratios help investors to determine whether Neuren Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Neuren with respect to the benefits of owning Neuren Pharmaceuticals security.